Deficiencies in certain physiological pathways are linked with ACE or
vasopeptidase inhibitor associated angioedema. Additionally, detection and/or measurement
of dipeptidyl peptidase IV (DPP IV) enzyme activity and aminopeptidase P (APP)
enzyme activity is a predictor of this risk. The present invention provides biological
markers, diagnostic tests, and pharmaceutical indications that are useful in the
diagnosis and treatment of angioedema and in the marketing and safety of certain
medications. This ability can be important for the treatment of a subject that
is in need of or are taking an angiotensin-converting enzyme (ACE) inhibitor and/or
a vasopeptidase inhibitor (combined ACE and neutral endopeptidase (NEP) inhibitor),
which are commonly used in the treatment of hypertension (high blood pressure),
diabetes, and cardiac and renal diseases.
